AMXI-5001

P1/2, N=122, Recruiting, AtlasMedx, Incorporated | Active, not recruiting --> Recruiting | Trial completion date: Jan 2025 --> Oct 2026 | Trial primary completion date: Jan 2025 --> Aug 2026

P1/2, N=122, Active, not recruiting, AtlasMedx, Incorporated | Recruiting --> Active, not recruiting

P1/2, N=122, Recruiting, AtlasMedx, Incorporated | N=80 --> 122 | Trial completion date: Jan 2023 --> Jan 2025 | Trial primary completion date: Jan 2023 --> Jan 2025

AMXI-5001 demonstrates comparable IC50 inhibition against PARP and microtubule polymerization as clinical PARP inhibitors (Olaparib, Rucaparib, Niraparib, and Talazoparib) and the potent polymerization inhibitor (Vinblastine), respectively. AMXI-5001 resulted in superior anti-tumor effects compared to either single agent (PARP or microtubule) inhibitor or combination with both agents. AMXI-5001 will enter clinical trial testing soon and represents a promising, novel first in class dual PARP1/2 and microtubule polymerization inhibitor that delivers continuous and synchronous one-two punch cancer therapy with one molecule.